Asunercept companion diagnostic - Apogenix/R Biopharm

Drug Profile

Asunercept companion diagnostic - Apogenix/R Biopharm

Alternative Names: APG101 companion diagnostic; Apocept™ companion diagnostic; Asinercept companion diagnostic; CD95-Fc fusion protein companion diagnostic

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apogenix; R-Biopharm
  • Developer Apogenix
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Clinical Phase Unknown Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 09 Jun 2017 Phase-II development for Glioblastoma (Diagnosis) is ongoing in Germany (Apogenix pipeline, June 2017)
  • 07 Oct 2016 Biomarker data from a phase II trial in Glioblastoma presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 16 Feb 2016 Apogenix receives other grant from German Federal Ministry of Education and Research for Asunercept companion diagnostic development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top